Cargando…

Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil

BACKGROUND: Despite the advances in therapy, the occurrence of drug-resistant human immunodeficiency virus type 1 (HIV-1) is a major obstacle to successful treatment. This study aimed to characterize the genetic diversity and to determine the prevalence of transmitted drug resistance mutations (TDRM...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahls, Larissa Danielle, Canezin, Pedro Henrique, Reiche, Edna Maria Vissoci, Fernandez, José Carlos Couto, Dias, José Ricardo Colleti, Meneguetti, Vera Alice Fernandes, Ueda, Luis Toshio, Bertolini, Dennis Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364409/
https://www.ncbi.nlm.nih.gov/pubmed/30722787
http://dx.doi.org/10.1186/s12981-019-0219-1
Descripción
Sumario:BACKGROUND: Despite the advances in therapy, the occurrence of drug-resistant human immunodeficiency virus type 1 (HIV-1) is a major obstacle to successful treatment. This study aimed to characterize the genetic diversity and to determine the prevalence of transmitted drug resistance mutations (TDRM) between individuals recently or chronically diagnosed with HIV-1 from Paraná, Brazil. METHODS: A total of 260 HIV-1 positive antiretroviral therapy-naïve patients were recruited to participate on the study, of which 39 were recently diagnosed. HIV-1 genotyping was performed using sequencing reaction followed by phylogenetic analyses to determine the HIV-1 subtype. TDRM were defined using the Calibrated Population Resistance Tool program. RESULTS: The HIV-1 subtypes frequency found in the studied population were 54.0% of subtype B, 26.7% subtype C, 6.7% subtype F1 and 12.7% recombinant forms. The overall prevalence of TDRM was 6.7%, including 13.3% for recently diagnosed subjects and 5.9% for the chronic group. CONCLUSIONS: The prevalence of resistance mutations found in this study is considered moderate, thus to perform genotyping tests before the initiation of antiretroviral therapy may be important to define the first line therapy and contribute for the improvement of regional prevention strategies for epidemic control. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12981-019-0219-1) contains supplementary material, which is available to authorized users.